Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

FDA’s Long-Awaited QMSR Final Rule Harmonizes U.S. and Intl. Device Requirements

  • Post author:PacConAdmin
  • Post published:January 31, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has released its long-awaited Quality Management System Regulation (QMSR) final rule, including a change that requires medical device manufacturers to be compliant within two years instead of the…

Continue ReadingFDA’s Long-Awaited QMSR Final Rule Harmonizes U.S. and Intl. Device Requirements

Controversial Alzheimer’s Drug Aduhelm, Now Pulled, Made History

  • Post author:PacConAdmin
  • Post published:January 31, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Biogen is officially pulling the plug on Aduhelm, the controversial antiamyloid antibody that dragged the company through a Congressional investigation, spurred the resignation of a top FDA official, and crashed…

Continue ReadingControversial Alzheimer’s Drug Aduhelm, Now Pulled, Made History

AdvaMed Asks Congress to Pass Tax Provision That Delays 5-Year R&D Deduction

  • Post author:PacConAdmin
  • Post published:January 31, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

AdvaMed has urged Congress to pass the Tax Relief for American Families and Workers Act of 2024 (H.R.7024) that contains a tax change that would allow businesses to deduct their…

Continue ReadingAdvaMed Asks Congress to Pass Tax Provision That Delays 5-Year R&D Deduction

35 Briefs Supporting FDA Submitted to U.S. Supreme Court on Mifepristone Decision

  • Post author:PacConAdmin
  • Post published:January 31, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Thirty-five amicus briefs on the issue of the FDA’s approval of the abortion drug mifepristone landed in the Supreme Court of U.S. on Tuesday, all in support of the FDA’s…

Continue Reading35 Briefs Supporting FDA Submitted to U.S. Supreme Court on Mifepristone Decision

FDA Offers Final Draft of Best Practices for Postmarketing Safety Surveillance

  • Post author:PacConAdmin
  • Post published:January 30, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

Responding to changes required by the 21st Century Cures Act, the FDA has unveiled its principles for post market surveillance of drug safety in the final version of a 2019…

Continue ReadingFDA Offers Final Draft of Best Practices for Postmarketing Safety Surveillance

FDA Must Respond to Vanda Request for Answers on Drug Denial, Court Rules

  • Post author:PacConAdmin
  • Post published:January 30, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has until March 5 to provide an answer for Vanda Pharmaceuticals’ five-year quest to understand why the FDA denied the company’s supplemental New Drug Application (sNDA) for Hetlioz…

Continue ReadingFDA Must Respond to Vanda Request for Answers on Drug Denial, Court Rules

FDA Elevates Office of Strategic Partnerships and Technology Innovation to Super Office

  • Post author:PacConAdmin
  • Post published:January 30, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The CDRH Office of Strategic Partnerships and Technology Innovation (OST) has been elevated to a super office, effective immediately, a designation that the FDA says will allow OST to adapt…

Continue ReadingFDA Elevates Office of Strategic Partnerships and Technology Innovation to Super Office

FDA Expands In-Person Face-to-Face Meetings for PDUFA, BsUFA, OMUFA

  • Post author:PacConAdmin
  • Post published:January 30, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

The FDA has expanded its use of in-person face-to-face (FTF) meetings for additional application types, and have expanded its definition of FTF meetings to include hybrid meetings which combine in-person…

Continue ReadingFDA Expands In-Person Face-to-Face Meetings for PDUFA, BsUFA, OMUFA

Legislative Update — Week of Jan. 29, 2024

  • Post author:PacConAdmin
  • Post published:January 29, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

As the second session of the 118th Congress begins, FDAnews will track important pending legislation, that has been acted on since Oct. 1, 2023 to keep you updated on laws…

Continue ReadingLegislative Update — Week of Jan. 29, 2024

Quick Notes: European Edition — Jan. 29, 2024

  • Post author:PacConAdmin
  • Post published:January 29, 2024
  • Post category:Uncategorized
  • Post comments:0 Comments

In this edition of Quick Notes, we hop across the pond to check out the EMA’s new regulatory fees structure, its updated submissions communication portal, and the sixth update of…

Continue ReadingQuick Notes: European Edition — Jan. 29, 2024
  • Go to the previous page
  • 1
  • …
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.